These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 3878765)
1. Increased plasma levels of the terminal complement complex in patients with evidence of complement activation. Mollnes TE; Frøland SS; Harboe M Complement; 1985; 2(2-3):175-84. PubMed ID: 3878765 [TBL] [Abstract][Full Text] [Related]
2. Local and systemic activation of the whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers. Dauchel H; Joly P; Delpech A; Thomine E; Sauger F; Le Loet X; Lauret P; Tron F; Fontaine M; Ripoche J Clin Exp Immunol; 1993 May; 92(2):274-83. PubMed ID: 8485913 [TBL] [Abstract][Full Text] [Related]
3. Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex. Mollnes TE Complement; 1985; 2(2-3):156-64. PubMed ID: 3878764 [TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328 [TBL] [Abstract][Full Text] [Related]
5. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro. Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694 [TBL] [Abstract][Full Text] [Related]
6. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases. Horigome I; Seino J; Sudo K; Kinoshita Y; Saito T; Yoshinaga K Clin Exp Immunol; 1987 Nov; 70(2):417-24. PubMed ID: 3427827 [TBL] [Abstract][Full Text] [Related]
7. An enzyme-linked immunoabsorbent assay for the quantitation of the terminal complement complex from cell membranes or in activated human sera. Gawryl MS; Simon MT; Eatman JL; Lint TF J Immunol Methods; 1986 Dec; 95(2):217-25. PubMed ID: 3794343 [TBL] [Abstract][Full Text] [Related]
8. [Terminal complement complex (TTC) levels in plasma and urine from glomerular diseases: enzyme-linked immunosorbent assay (ELISA) using monoclonal antibody against neoantigens of TCC]. Kusunoki Y Hokkaido Igaku Zasshi; 1990 Jan; 65(1):74-85. PubMed ID: 2328949 [TBL] [Abstract][Full Text] [Related]
9. C3, C4, and the terminal complement complex differ from C1q by binding predominantly to the antigenic part of solid phase immune complexes. Garred P; Michaelsen TE; Aase A; Mollnes TE J Immunol; 1990 Jan; 144(1):198-203. PubMed ID: 2295791 [TBL] [Abstract][Full Text] [Related]
10. Comparative study of assays detecting complement activation. Complement-split product C3d (rocket immuno-electrophoresis) and C3d neodeterminants (ELISA). Espersen GT; Langeland B; Grunnet N Scand J Clin Lab Invest; 1990 Jun; 50(4):389-93. PubMed ID: 1697427 [TBL] [Abstract][Full Text] [Related]
11. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Mollnes TE; Lea T; Frøland SS; Harboe M Scand J Immunol; 1985 Aug; 22(2):197-202. PubMed ID: 2412280 [TBL] [Abstract][Full Text] [Related]
12. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65. Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of in vivo immune complex formation and complement activation in patients receiving intravenous streptokinase. Freysdottir J; Ormarsdottir S; Sigfusson A Clin Exp Immunol; 1993 Nov; 94(2):286-90. PubMed ID: 8222319 [TBL] [Abstract][Full Text] [Related]
14. Quantification of the C3d split products of human complement by a sensitive enzyme-linked immunosorbent assay. Mollnes TE Scand J Immunol; 1985 Jun; 21(6):607-13. PubMed ID: 3895396 [TBL] [Abstract][Full Text] [Related]
16. [Activation of complement by hemodialysis membrane]. Kojima H; Ohi H; Seki M; Sakamoto K; Hatano M; Sudou S; Sudou Y Nihon Jinzo Gakkai Shi; 1989 Jan; 31(1):91-7. PubMed ID: 2747003 [TBL] [Abstract][Full Text] [Related]
17. Accentuated formation of the terminal C5b-9 complement complex in patient plasma precedes development of the adult respiratory distress syndrome. Langlois PF; Gawryl MS Am Rev Respir Dis; 1988 Aug; 138(2):368-75. PubMed ID: 3264125 [TBL] [Abstract][Full Text] [Related]
19. Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay. Mollnes TE; Lachmann PJ J Immunol Methods; 1987 Aug; 101(2):201-7. PubMed ID: 2440954 [TBL] [Abstract][Full Text] [Related]
20. Evidence suggesting the occurrence of C3-independent intravascular immune hemolysis. Reactive hemolysis in vivo. Salama A; Bhakdi S; Mueller-Eckhardt C Transfusion; 1987; 27(1):49-53. PubMed ID: 3810824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]